Name | FGH10019 |
---|---|
Synonyms |
Methanesulfonamide, N-[4-[2-(2-propyl-4-pyridinyl)-4-thiazolyl]phenyl]-
N-{4-[2-(2-Propyl-4-pyridinyl)-1,3-thiazol-4-yl]phenyl}methanesulfonamide |
Description | FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC50 of 1 μM. |
---|---|
Related Catalog | |
Target |
IC50: 1 μM (SREBP) |
In Vitro | Treatment of the CHO-K1 cells with analog FGH10019 decreases the percentage of the mature form of SREBP-2 (68 kDa) at lower concentrations than treatment with fatostatin. Densitometric analysis of the gels indicates that the IC50 of analog FGH10019 is approximately 1 μM, which is 5-10 times lower than the IC50 of fatostatin (appr 10 μM)[1]. |
In Vivo | FGH10019-treated chow is fed at a dose rate calculated to provide about 0.7 mg analog FGH10019 per day, at about 23 mg/kg body weight, to 5-wk-old male ob/ob mice weighing an average of appr 30 g. After 8 wk on the analog 24-treated chow, the mice gain 8-9 % less weight than control mice[1]. |
Animal Admin | Five-week-old homozygous male obese (ob/ob) mice (C57BL/6J) are housed five per cage, and had ad libitum access to normal chow and water for 1 wk after their arrival. On day 1 of the experiment, the animals (10 per group) are fed normal chow (control diet) or chow that contains 200 mg/kg of analogue 24. These doses are estimated to provide approximately 0.7 mg analogue 24 per day (appr 23 mg/kg body weight per day). Daily food intake and body weight are carefully monitored and recorded between 3:00 and 5:00 p.m. Serum constituents, and TG levels in livers are determined. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 578.4±60.0 °C at 760 mmHg |
Molecular Formula | C18H19N3O2S2 |
Molecular Weight | 373.492 |
Flash Point | 303.6±32.9 °C |
Exact Mass | 373.091858 |
LogP | 3.97 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.624 |
Storage condition | 2-8℃ |